Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice

C Xiao, FJ Davis, BC Chauhan… - Journal of …, 2013 - content.iospress.com
C Xiao, FJ Davis, BC Chauhan, KL Viola, PN Lacor, PT Velasco, WL Klein, NB Chauhan
Journal of Alzheimer's Disease, 2013content.iospress.com
Alzheimer's disease (AD) is a global health crisis with limited treatment options. Despite
major advances in neurotherapeutics, poor brain penetration due to the blood-brain barrier
continues to pose a big challenge in overcoming the access of therapeutics to the central
nervous system. In that regard, the non-invasive intranasal route of brain targeting is gaining
considerable attention. The nasal mucosa offers a large surface area, rapid absorption, and
avoidance of first-pass metabolism increasing drug bioavailability with less systemic side …
Abstract
Alzheimer’s disease (AD) is a global health crisis with limited treatment options. Despite major advances in neurotherapeutics, poor brain penetration due to the blood-brain barrier continues to pose a big challenge in overcoming the access of therapeutics to the central nervous system. In that regard, the non-invasive intranasal route of brain targeting is gaining considerable attention. The nasal mucosa offers a large surface area, rapid absorption, and avoidance of first-pass metabolism increasing drug bioavailability with less systemic side effects. Intranasal delivery is known to utilize olfactory, rostral migratory stream, and trigeminal routes to reach the brain. This investigation confirmed that intranasal delivery of oligomeric amyloid-ß antibody (NU4) utilized all three routes to enter the brain with a resident time of 96 hours post single bolus intranasal administration, and showed evidence of perikaryal and parenchymal uptake of NU4 in 5XFAD mouse brain, confirming the intranasal route as a non-invasive and efficient way of delivering therapeutics to the brain. In addition, this study demonstrated that intranasal delivery of NU4 antibody lowered cerebral amyloid-ß and improved spatial learning in 5XFAD mice.
content.iospress.com